Current Reviews in Clinical and Experimental Pharmacology is a cutting-edge journal published by Bentham Science Publishers in the United Arab Emirates, focusing on the dynamic field of pharmacology. With an ISSN of 2772-4328 and an E-ISSN of 2772-4336, this journal has rapidly established itself as a significant resource for researchers and professionals in the medical and pharmaceutical sciences since its inception in 2021. It boasts an impressive Q3 ranking in Pharmacology (medical) and Q2 in the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) category as of 2023. Furthermore, it ranks #14/80 in general pharmacology, reflecting its esteemed position within the scientific community. As an Open Access publication, it ensures that groundbreaking research is readily accessible, fostering collaboration and innovation. The journal invites high-quality reviews and original articles that address contemporary issues and advancements in clinical and experimental pharmacology, making it an essential venue for disseminating knowledge and engaging with emerging trends in therapeutic developments.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Asian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.

New Armenian Medical Journal (ISSN: 1829-0825, E-ISSN: 1829-0825) is a prominent academic publication established by Yerevan State Medical University, dedicated to advancing the field of medicine through high-quality research and scholarly discourse. Located in Armenia, this journal serves as a vital platform for disseminating innovative findings and clinical practices, with a particular focus on the regional healthcare landscape as well as global health issues. While currently categorized in the lower quartile (Q4) of general medicine, it demonstrates a commitment to improving its impact factor and ranking, evidenced by its ongoing publication from 2009 to 2024. The journal embraces a diverse scope that encompasses miscellaneous topics within medical research, catering to the needs of practitioners, researchers, and students alike. Though not an open-access journal, it offers valuable insights and knowledge that contribute meaningfully to the medical community. By participating in this scholarly dialogue, readers can enhance their understanding and foster advancements in the ever-evolving field of medicine.

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

European Journal of Therapeutics is a distinguished journal dedicated to advancing the field of therapeutic sciences through high-quality research and innovative clinical practice. Published by Pera Yayincilik Hizmetleri, this interdisciplinary journal aims to facilitate knowledge dissemination in areas such as pharmacology, clinical medicine, and public health, thereby supporting both researchers and practitioners in improving therapeutic outcomes. Although the journal operates under a subscription model, its commitment to rigorous peer review ensures that published articles reflect the latest advancements and methodologies. With a growing emphasis on evidence-based therapies, the European Journal of Therapeutics serves as a vital platform for dialogue among healthcare professionals and researchers, enhancing the understanding of therapeutic interventions on a global scale. It welcomes contributions ranging from original research to review articles, making it an essential resource for those seeking to enrich their knowledge and influence practice in therapeutic approaches.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE is a premier peer-reviewed academic journal published by WILEY-HINDAWI, dedicated to advancing the field of clinical medicine. With an ISSN of 1368-5031 and E-ISSN 1742-1241, this open access journal has been providing a platform for insightful research since its inception in 1997 and continues to contribute significantly to the medical community, as indicated by its Q2 ranking in Medicine (miscellaneous) for 2023 and its position in the top 15% of Scopus-ranked journals. The journal invites innovative studies, systematic reviews, and clinical trials, making it a critical resource for healthcare professionals, researchers, and students seeking to stay updated on the latest clinical practices. Based in the United Kingdom at Adam House, 3rd Fl, 1 Fitzroy Sq, London W1T 5HE, this journal supports open accessibility, enhancing the dissemination of vital research findings across the globe. Join the growing community of scholars who contribute to and benefit from this influential publication as it continues to shape the future of clinical practice.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.